用贝叶斯模型平均灵活评估替代标志物
针对随机临床试验中替代标志物评估问题,提出贝叶斯模型平均方法估计替代标志物所解释的治疗效应比例,通过平均多个候选模型兼顾参数模型推断优势与非参数灵活性。模拟研究显示在替代支持不一致和小样本时具优势,并用糖尿病预防计划数据考察糖化血红蛋白作为空腹血糖替代标志物。
要点
- 贝叶斯模型平均法估计替代标志物解释的治疗效应比例。
- 该方法在替代支持不一致和小样本时较既往方法有优势。
- 以糖尿病预防计划数据评估糖化血红蛋白替代空腹血糖。
核心结论
- 提出的贝叶斯模型平均方法在模型灵活性与参数推断之间取得折中,用于估计替代标志物所解释的治疗效应比例。
研究设计与样本
- 方法学研究,提出贝叶斯模型平均方法并与既往基于模型的方法及非参数方法进行比较。
- 通过模拟研究评估方法性能,并使用糖尿病预防计划研究数据做实例分析。
主要发现
- 模拟研究表明,当替代支持不一致且样本量小时,本方法具有优势。
- 基于模型的方法可能受模型误设影响,非参数方法在样本量小或数据范围不满足特定条件时估计不理想。
关键数值与推荐
- 以糖尿病预防计划研究数据考察糖化血红蛋白作为空腹血糖的替代标志物。
局限性
- 基于模型的方法存在模型潜在误设的问题。
- 非参数方法在样本量小或数据范围不满足特定条件时无法给出理想估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
When long-term follow up is required for a primary endpoint in a randomized clinical trial, a valid surrogate marker can help to estimate the treatment effect and accelerate the decision process. Several model-based methods have been developed to evaluate the proportion of the treatment effect that is explained by the treatment effect on the surrogate marker. More recently, a nonparametric approach has been proposed allowing for more flexibility by avoiding the restrictive parametric model assumptions required in the model-based methods. While the model-based approaches suffer from potential mis-specification of the models, the nonparametric method fails to give desirable estimates when the sample size is small, or when the range of the data does not follow certain conditions. In this paper, we propose a Bayesian model averaging approach to estimate the proportion of treatment effect explained by the surrogate marker. Our procedure offers a compromise between the model-based approach and the nonparametric approach by introducing model flexibility via averaging over several candidate models and maintains the strength of parametric models with respect to inference. We compare our approach with previous model-based methods and the nonparametric method. Simulation studies demonstrate the advantage of our method when surrogate supports are inconsistent and sample sizes are small. We illustrate our method using data from the Diabetes Prevention Program study to examine hemoglobin A1c as a surrogate marker for fasting glucose.
引用
- Duan Y, Parast L. Flexible evaluation of surrogate markers with Bayesian model averaging. Stat Med. 2023. PMID: 38081586. doi:10.1002/sim.9986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。